Blood-based biomarker tests for colorectal cancer could soon be cleared by U.S. regulators, opening the doors to a new, more convenient way to screen for the disease.
If colon cancer blood tests eventually win FDA approval and Medicare reimbursement, their use could become more widespread. But first this approach needs to match up against the current standard.
Researchers have created novel scoring tools for predicting actual risk of colon cancer and advanced precancerous polyps for patients at average for the disease.